News
Resources
Blog
Sites
Medicare Monday: Medicare turns 52!
By Nicole Longo | July 31, 2017
This weekend (July 30) marked 52 years since Medicare was signed into law by President Lyndon B. Johnson as a part of the Social Security Act Amendments. To celebrate the occasion, we are taking a...
Read More
Video: PhRMA CEO discusses medicine costs with CNBC's Squawk Box
By Holly Campbell | July 31, 2017
PhRMA president and CEO Stephen J. Ubl joined Squawk Box this morning to put medicine costs and spending in context, the biopharmaceutical supply chain and policy solutions to address cost concerns...
Read More
Putting the bio in biotech: How Bay Area minds are powering biopharmaceutical innovation
By Andrew Powaleny | July 31, 2017
The Bay Area in California has long been considered a nucleus of innovation, having produced groundbreaking inventions and discoveries over the last few decades – spanning nearly every industry, from...
Read More
Biopharmaceutical industry policies aim to increase access to clinical trial data
By Olivia Shopshear | July 27, 2017
Today, a study published in the British Medical Journal (BMJ) sought to audit industry clinical trial disclosure and data sharing policies. The study, entitled Pharmaceutical companies’ policies on...
Read More
Opportunities to build upon enhanced competition for medicines in the marketplace
By David Korn | July 27, 2017
Last week, I presented at the U.S Food and Drug Administration’s (FDA) public meeting on the Hatch-Waxman Amendments to discuss the balance between encouraging innovation in biopharmaceutical...
Read More
Finding cures for incurable diseases
By Guest Contributor | July 25, 2017
By Sandra Raymond, president and CEO, The Lupus Foundation of America
Read More
Medicare Monday: How Part B has evolved over the years
By Nicole Longo | July 24, 2017
With Medicare’s birthday rapidly approaching (July 30!), today we’re highlighting a few of the ways reimbursement for physician-administered medicines under Part B has changed since it was first...
Read More
Guest Post: Policy conditions make or break leaders in biopharmaceutical innovation: Preliminary results from the 2017 BCI Survey
By Guest Contributor | July 24, 2017
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
New PhRMA resources chock full of biopharma industry facts
By John Corea | July 20, 2017
Did you know that PhRMA member companies invested $65.5 billion in research and development (R&D) in 2016? Or that combined spending on brand medicines, generics and the supply chain account for 14...
Read More
New video: Patient and researcher fight JRA together
By Amber Lyons | July 19, 2017
Have you ever heard of juvenile rheumatoid arthritis (JRA)? A lot of people haven’t.
Read More
New report portrays flourishing pipeline
By Gretta Stone | July 18, 2017
It’s an exciting time to be working in the biopharmaceutical industry. Almost every day new headlines highlight remarkable new advances in the fight against disease. Some have called this the golden...
Read More
Medicare Monday: What you need to know about the latest Medicare Trustees report
By Nicole Longo | July 17, 2017
Last week, the Trustees of the Social Security and Medicare trust funds released its annual report on the current and projected financial status of Medicare. Here are a few important takeaways in...
Read More
340B Spotlight: New analysis finds 340B program growth continues to accelerate despite false claims
By Nicole Longo | July 13, 2017
This week, Berkeley Research Group (BRG) released a new whitepaper pushing back on the highly misleading claim that 340B sales are only 2 percent of annual U.S. drug sales. Citing a number of...
Read More
Why reauthorization of PDUFA matters
By Andrew Powaleny | July 13, 2017
Last night, the Prescription Drug User Fee Act (PDUFA), was reauthorized by the House of Representatives. PDUFA provides the U.S. Food and Drug Administration (FDA) with necessary resources to meet...
Read More
New “Let’s Talk About Cost” campaign convenes national dialogue on medicine costs
By Robert Zirkelbach | July 12, 2017
Discussions about costs are important. We recognize that many are struggling to access the medicine they need and have important questions about their medicine costs. And we want to help find the...
Read More
Going boldly together: New advancements and new anniversaries
By Amber Lyons | July 11, 2017
Hopefully you’ve had the chance to meet Salim and Roxanne from our Together series on GoBoldly.com. Salim is an antirejection researcher and Roxanne had a heart transplant 7 years ago this week and...
Read More
Poll respondents appreciate economic benefits of innovation and call for more protections
By Mark Grayson | July 11, 2017
Increasingly, economists and international organizations are recognizing innovation as one of the most important drivers of economic and social progress and stability. In fact, a report released...
Read More
Medicare Monday: Study finds mortality rates for elderly have decreased every year since creation of Part D
By Nicole Longo | July 10, 2017
On Medicare Monday, we’ve talked about how Medicare Part D’s competitive structure improves access to affordable prescription drug coverage for seniors and individuals with disabilities. We’ve also...
Read More
Medicare Monday: It is Medicare’s birthday month!
By Nicole Longo | July 3, 2017
On July 30, 1965, Medicare was signed into law by President Lyndon B. Johnson, so this week we’re kicking off Medicare’s birthday month with a look back at some of our favorite resources.
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
